Oct 13, 2016
Pharmaceutical Executive
The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do they mean for pharma players in the world’s third-largest market?
Oct 12, 2016
Pharmaceutical Executive
The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.
Oct 05, 2016
If Richard Bergström was not already planning his departure as Director General of EFPIA, his appearance at last week’s European Health Forum Gastein might have pushed him towards it.
Sep 22, 2016
The UK is moving closer to aligning its two approaches to regulating drug pricing — the voluntary PPRS and statutory price cuts — but the headaches are likely to continue, writes Leela Barham.
Sep 15, 2016
By Pharmaceutical Executive Editors
EFPIA's Richard Bergström warns of a return to the "dark ages of medicine" in Europe.
Sep 09, 2016
Japanese pharma has voiced Brexit concerns, but it favored London as a European base well before the EMA opened its doors.
Sep 08, 2016
Pharmaceutical Executive
As the UK exits the European Union, pharma should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Sep 07, 2016
Leela Barham reviews NHS England's proposals for the creation of Regional Medicines Optimization Committees.
Aug 15, 2016
Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.
Aug 10, 2016
If managed access is to be a widely available option, it makes sense to re-assess just how much should be spent on it, writes Leela Barham.
lorem ipsum